MRUS - Merus N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.90
+0.51 (+3.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.39
Open16.29
Bid16.41 x 1100
Ask20.00 x 800
Day's Range15.81 - 16.90
52 Week Range14.05 - 26.74
Volume7,432
Avg. Volume42,983
Market Cap382.494M
Beta (3Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-2.64
Earnings DateNov 28, 2018 - Dec 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.63
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    Merus to Present at the Cantor Fitzgerald Global Healthcare Conference

    UTRECHT, The Netherlands, Sept. 27, 2018-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Hui Liu, Ph.D., Executive Vice ...

  • GlobeNewswire21 days ago

    Merus Strengthens Team with Key Appointments

    Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will assume additional responsibilities as Head of Merus U.S. Peter B. Silverman, J.D., has been appointed as Executive Vice President and General Counsel.

  • GlobeNewswire2 months ago

    Merus to Participate in Citi’s 13th Annual Biotech Conference

    UTRECHT, The Netherlands, Aug. 30, 2018-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., President ...

  • GlobeNewswire2 months ago

    Merus Announces Formation of a Scientific Advisory Board

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals. The SAB will collaborate with members of Merus’ management team to support the advancement of the Company’s pipeline of Biclonics® candidates for various oncology indications.

  • GlobeNewswire2 months ago

    Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DURECT ...

  • GlobeNewswire2 months ago

    Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results

    UTRECHT, The Netherlands, Aug. 10, 2018-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ...

  • GlobeNewswire2 months ago

    Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference

    UTRECHT, The Netherlands, Aug. 07, 2018-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Hui Liu, Ph.D., Executive Vice ...

  • GlobeNewswire3 months ago

    Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

    - Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128`s unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The ...

  • GlobeNewswire3 months ago

    Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

    -Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors-. -MCLA-128’ s unique mechanism of action published in the scientific journal Cancer Cell-. UTRECHT, The ...

  • GlobeNewswire3 months ago

    Merus Announces Annual Meeting of Shareholders

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the `Investor Relations` section of Merus` website (www.merus.nl) under "Financial Information". Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®.

  • GlobeNewswire5 months ago

    Merus to Present at the Jefferies 2018 Healthcare Conference

    UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today ...

  • GlobeNewswire5 months ago

    Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018.

  • GlobeNewswire5 months ago

    Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

    "This study demonstrates the power of empirical functional screening to unlock innovative biology unique to the bispecific antibody format," said Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Officer of Merus. Using unbiased combinatorial screening, we identified a bispecific antibody that employs a unique mechanism to selectively and potently block signaling down this pathway (Dock & Block(TM)). The development candidate advanced from this work, MCLA-128, is being evaluated in multiple clinical studies where this pathway is believed to drive tumor growth and resistance to existing standard of care therapies.

  • ACCESSWIRE6 months ago

    Blog Exposure - VIVUS to Acquire Janssen Pharma’s PANCREAZE(R) Capsules in the United States and Canada

    LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on VIVUS, Inc. (NASDAQ: VVUS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VVUS as the Company's latest news hit the wire. On May 01, 2018, the Company announced that it has inked an agreement to acquire all of the product rights for Janssen Pharmaceuticals, Inc.'s PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada, for approximately $135 million.

  • GlobeNewswire6 months ago

    Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017

    - Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus` most advanced bispecific antibody candidate, MCLA-128 - - Strategic collaboration announced with Simcere ...

  • ACCESSWIRE6 months ago

    Merus N.V. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Merus N.V. (NASDAQ: MRUS ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 26, 2018 at 8:30 AM Eastern Time. To listen ...

  • GlobeNewswire6 months ago

    Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

    Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing ...

  • Incyte Advances R&D Strategy with Multiple Partnerships
    Market Realist6 months ago

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.